Compare Amgen, Inc. (AMGN) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? Amgen, Inc. trades at $356.51 (market cap $196.12B), while Virgin Galactic Holdings, Inc. trades at $2.42 (market cap $330.34M). The key difference: Amgen, Inc. is far larger — about 593.7× Virgin Galactic Holdings, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | SPCE | |
|---|---|---|
Market Cap | $196.12B | $330.34M |
Sector | Health | Industrials |
52-Week High | $388.16 | $7.52 |
52-Week Low | $271.18 | $2.17 |
Enterprise Value | $241.41B | $430.19M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Virgin Galactic (SPCE) trades at $2.57, down 1.91% on the day, with a bearish technical signal from moving averages. The company continues to report significant losses with negative gross profit margins of -6,127.71% and net income margin of -19,781.3% for 2025. Recent news highlights volatility in space stocks following SpaceX's IPO, with SPCE experiencing sharp price swings. Cash flow remains negative at -$35.17 million for 2025, though showing improvement from previous years.
The outlook remains challenging with persistent operational losses and high cash burn. Investment opportunity exists if the company can achieve commercial scale and profitability, but risks include execution challenges, competitive pressure, and dependence on additional financing. Analyst consensus is divided with 29% buy, 41% hold, and 29% sell ratings, reflecting uncertainty about the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
